Clinical trial
Use of Topotecan in Patients With Refractory Acute Leukemia
NCT00100477 · US Department of Veterans Affairs, U.S. Fed · Completed
Key facts
| NCT number | NCT00100477 |
|---|---|
| Title | Use of Topotecan in Patients With Refractory Acute Leukemia |
| Official title | Study of Topoisomerase Inhibition in the Treatment of Acute Leukemia |
| Lead sponsor | US Department of Veterans Affairs, U.S. Fed |
| Collaborators | Immunex Corporation Industry SmithKline Beecham Amgen |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Non-Hodgkin's Lymphoma, Leukemia |
| Intervention type | Drug |
| Interventions | Topotecan, Mitozantrone, Etoposide |
| Enrollment | 10 |
| Start date | Aug 1, 1998 |
| Primary completion | Jan 1, 2001 |
| Completion | Jun 1, 2001 |
| First posted | Dec 31, 2004 |
| Last update posted | Sep 25, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: